Reading Time: 7 minutes

In our previous blog, we explained what biomarkers are and what they can be used for. In this blog, we dive further into the world of biomarkers, specifically looking at how they might be used in MND.

Why are biomarkers needed for MND?

There are currently no tests that can say for sure that someone does or does not have MND. Instead, MND is typically diagnosed after a process of elimination, once other diseases, which cause similar symptoms, have been ruled out. This elimination process can result in long diagnostic delays while the symptoms are initially thought to be caused by another problem. By the time someone gets a diagnosis of MND, symptoms can already be very advanced and affecting both the arms and legs and the bulbar muscles (the muscles that affect breathing and swallowing). The delay getting a diagnosis can also delay access to MND specific care and support, as well as access to clinical trials and potential treatments.

There is also a lot of variation in how long people live for when they have been diagnosed with MND. Although the average survival is 3 years from diagnosis, some people’s symptoms progress much faster than this and other people may progress much slower than this. Researchers are getting closer to understanding why there are differences in disease progression. However, for someone who has just been diagnosed with MND, there is currently no way of knowing how quickly their disease will progress.

This is where biomarkers can help

Researchers are looking for markers in the body, such as specific molecules that can be detected in body fluids, or changes in the body that can be seen with imaging, that will help to diagnose MND. If someone presents to their neurologist with symptoms of MND that could be mistaken for another disease, measuring biomarkers may help to determine whether the person has MND more quickly. If there is a way of finding a unique ‘signature’ of MND, by, for example, taking a blood sample or taking a scan of the brain and spinal cord, this would help to enable faster diagnoses which could lead to earlier access to care, potential treatments and clinical trials.

Biomarkers are also needed for MND to tell the difference between someone with fast-progressing disease and someone with slow-progressing disease. This could mean that when someone is diagnosed with MND, they will be given more accurate predictions about how fast their MND is likely to progress. Also, some drugs may only be effective in people with slow or fast progressing disease, so biomarkers may help to define these different groups and tell us more about which clinical trials or treatments people may be best suited to.

As there is currently no cure for MND, biomarkers can also help with drug discovery. If researchers can use biomarkers that are shared between models of MND and people with MND, they will be able to monitor the effects of potential treatments more accurately in MND models in the laboratory. This will mean that when drugs are tested in clinical trials, they are more likely to show the same effects that were seen in the models of MND.

Do we already have biomarkers for MND?

There are lots of different types of biomarkers currently being investigated for MND. One example of these is called Neurofilament.

Neurofilament is currently the most widely used biomarker in MND. But what exactly is it and how can it help people with MND?

Motor neurons are very long cells and, just like the Eiffel tower, they have a complex scaffolding structure that helps them to maintain their shape. Rather than being made of iron beams like the Eiffel tower, the scaffolding within a motor neuron is made up of proteins called neurofilaments. As motor neurons are the longest cells in the body, they contain more neurofilaments than any other type of cell in the body.

When someone has MND, this internal scaffolding can break down. When the motor neuron dies, the cell membrane, which is the outer layer of the cell, also begins to break. This means that the neurofilament proteins spill out of the cell and into the surrounding areas.

Neurofilament levels can be measured in the blood and cerebrospinal fluid (CSF). The amount of neurofilament in the blood and CSF is a direct indicator for neuron damage in the body. Although it is not specific for MND, higher levels of neurofilament are found in people with MND compared to healthy people.

If the level of neurofilament changes, it shows if there is a change to the amount of neuron damage in the body. This can be really useful for clinical trials, as we will explain in the next blog of the series.

Neurofilament also shows promise as an early detector of MND in people who do not have any symptoms. In people with a known risk of MND, for example those with a known genetic risk factor who do not yet have symptoms, monitoring of neurofilament levels might provide an indication of the disease developing before any symptoms appear. This could allow  pre-symptomatic carriers of MND risk genes to be recruited into clinical trials for preventative treatments.

But why have I heard it being called NfL?

To add just a little more complexity, neurofilament proteins can actually be categorised into three types. Neurofilament light chain (NfL), neurofilament medium chain (NfM) and neurofilament heavy chain (NfH). They are essentially just different types of scaffolding poles that all make up the internal skeleton in the neuron. Measuring just one specific type of neurofilament might provide a more accurate measure of disease diagnosis and progression than measuring all types together, but research is still confirming this.

Other biomarkers being studied for MND

There are many different biomarkers being studied to see if they could be good markers of disease progression and onset in MND. Click on the drop-down menu to find out more about some of the other types of biomarkers currently being studied for MND.

RNA biomarkers
Another type of biomarker being investigated in MND are RNAs, which are molecules that control what genes are made into proteins. RNAs are found in the blood, which makes them easily accessible through blood tests. They are also very stable in the blood, so they can be measured in the laboratory. This makes them ideal biomarker candidates. Finding one specific RNA that can be used as a biomarker of MND may be difficult, as some RNAs might be more or less active in multiple diseases, not just MND. However, when looking at a group of RNA biomarkers, it can form a unique RNA biomarker signature for MND.
P75 protein
P75 is the name of a protein that can only be detected in urine when there is damage to neurons. This is because the protein ‘sheds’ from neurons when they are damaged, a bit like neurofilament, and then makes its way out of the body in the urine. Although this isn’t a unique biomarker of MND, changes in the levels of p75 in the urine can show if there is an increase or decrease in the amount of neuron damage. This is a useful way of tracking disease progression in someone who has been diagnosed with MND.
Neuroimaging biomarkers
Alongside fluid-based biomarkers that can be removed from the body and measured in the lab, lots of research is currently exploring the potential of neuroimaging biomarkers for MND. This is done using various methods that look at the structure of the brain and spinal cord, such as magnetic resonance imaging (MRI), functional MRI (fMRI) and scans that look at the activity of the brain, such as a magnetoencephalogram (MEG). These scans might be able to find differences in the structure or function of parts of the brain and spinal cord that can be used as biomarkers for MND.
Muscle function tests
One biomarker that is often used to help inform a diagnosis of MND is changes in the electrical activity of muscles. When the brain sends signals to the muscle to move, the signal is carried through motor neurons in the form of electrical impulses. It is possible to measure the electrical activity of the muscles to show how many signals are passing to the muscles from motor neurons. This can directly indicate if the neurons connecting to the muscles are damaged. The technique used for this is called electromyography (EMG). It is an invasive method that requires a fine needle to be inserted into the muscles, which can be painful. It is very likely that someone being investigated for MND will have this test. Although the test cannot be used by itself to diagnose MND as it’s used for lots of neuromuscular diseases, the findings from these tests can confirm a diagnosis of MND or can suggest a different cause for symptoms. EMGs can also be useful to identify changes over time.

What about biomarkers for genetic MND?

Some research is focused on finding biomarkers specifically for genetic forms of MND. For example, people who have MND caused by mutations in the SOD1 gene can have higher amounts of SOD1 protein in their blood and CSF. This biomarker was actually used to monitor the effects of a gene therapy called Tofersen in clinical trials, as the drug was shown to reduce the amount of SOD1 protein in the CSF. You can read more about how biomarkers can be used in clinical trials in our next blog.

In clinical trials involving both familial MND and sporadic MND (where there is no known family history of MND), people with different genetic forms of MND may also respond differently to treatments. Biomarkers can help observe these differences and identify those with different forms of genetic MND. One such example was a trial examining the effect of lithium on MND symptoms. This trial identified that those who had a change in a gene called  UNC13A experienced different effects of lithium therapy compared to those without, even though overall the trial had a negative result. Lithium is now being re-tested in a clinical trial for people with MND who have the UNC13A gene change.

Biomarkers for genetic MND might one day be able to provide a quicker and easier way of knowing whether someone has a genetic form of MND than the current genetic testing methods, which are very expensive, slow and can be hard to access.

What is the future looking like for MND biomarkers?

Although there has been a lot of progress in the discovery of biomarkers for MND, there are still no definitive biomarkers for the diagnosis of MND.

The rapidly developing field of artificial intelligence and machine learning is offering more promise for the identification of new biomarkers. Combining modern intelligence technology with genetic, clinical, imaging and biomarker data might help to identify novel combinations of biomarkers that, when used together, can provide a more accurate insight into MND. This may help to provide more efficient ways of diagnosing, tracking progression of and treating MND.

Biomarkers can be an incredibly useful tool for clinical trials because they reduce the need to measure symptoms as an indicator of whether a drug is effective and provide a more accurate measure of whether a drug is able to slow disease progression. Read our next blog post to find out more about clinical trials.

The MND Association’s vision is a world free from MND. Realising this vision means investing more in research, further developing partnerships with the research community, funding bodies and industry, while ensuring that advances in understanding and treating MND are communicated as quickly and effectively as possible.

    Leave a Reply

    Your email address will not be published. Required fields are marked *


    The reCAPTCHA verification period has expired. Please reload the page.

    Discover more from MND Research Blog

    Subscribe now to keep reading and get access to the full archive.

    Continue reading